Clovis Oncology, Inc. announced that Dale Hooks has been named Senior Vice President and Chief Commercial Officer. Mr. Hooks succeeds Steve Hoerter, the Company's current Chief Commercial Officer and Executive Vice President, who is leaving to pursue other opportunities. Hooks joined Clovis in 2014 and has served as a key member of the commercial leadership team involved in preparation for the potential launches of the Company's late-stage investigational compounds, including rociletinib, for which a New Drug Application (NDA) is currently on file with the U.S. FDA, and rucaparib, for which an NDA is planned during the second quarter of 2016.

As Chief Commercial Officer at Clovis, Hooks will be responsible for the global commercial efforts and will also serve on the Company's executive committee.